Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Summary as of May 16, 2018

May 16, 2018 - By Richard Doty

Charles River Laboratories International, Inc. (NYSE:CRL) Corporate Logo
Big Money Sentiment decreased to 1.08 in Q4 2017. It has change of 0.38, from 2017Q3’s 1.46. The ratio dived due to Charles River Laboratories International, Inc. positioning: 35 sold and 98 reduced. 39 funds amassed positions and 104 increased positions. Investors holded 44.95 million in 2017Q3 but now own 44.57 million shares or 0.83% less.
Teacher Retirement Systems Of Texas has 16,324 shs. Fil Ltd has invested 0.15% in Charles River Laboratories International, Inc. (NYSE:CRL). The Michigan-based World Asset has invested 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL). 357,567 are owned by Invesco. Oregon Public Employees Retirement Fund accumulated 17,562 shs or 0.03% of the stock. Fdx Advisors invested in 0.02% or 5,558 shs. Systematic Financial Mgmt Limited Partnership holds 13,689 shs or 0.03% of its capital. Tocqueville Asset Mgmt Limited Partnership owns 2,760 shs. Affinity Inv Advisors Ltd Liability Corporation owns 18,210 shs or 0.23% of their US capital. Moreover, Gam Holdg Ag has 0.06% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Ariel Invs Limited, Illinois-based fund reported 1.35M shs. Bancshares Of Ny Mellon Corp holds 0.02% or 802,660 shs. Hsbc Plc stated it has 0% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Pembroke Mgmt Limited accumulated 77,535 shs. Meeder Asset Management Incorporated invested 0.01% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL).

Charles River Laboratories International, Inc. had 22 selling transactions and 0 insider purchases since January 2, 2018. This’s net activity of $10.95 million. $98,499 worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Smith David Ross. CHUBB STEPHEN D also sold $312,172 worth of Charles River Laboratories International, Inc. (NYSE:CRL) shs. Barbo William D sold $250,741 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Wednesday, February 21. On Tuesday, March 6 Girshick Birgit sold $1.08M worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 9,893 shs. MILNE GEORGE M JR also sold $890,100 worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, March 9.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

In total 10 analysts cover Charles River (NYSE:CRL). “Buy” rating has 5, “Sell” are 0, while 5 are “Hold”. 50% are bullish. 11 are the (NYSE:CRL)’s analyst reports since December 13, 2017 according to StockzIntelligence Inc. On Tuesday, April 24 the stock has “Buy” rating by Jefferies. On Monday, January 22 the firm earned “Hold” rating by SunTrust. On Wednesday, March 14 the company was maintained by Morgan Stanley. On Wednesday, February 14 the rating was maintained by JP Morgan with “Overweight”. On Friday, April 20 the firm has “Hold” rating by MUFG Securities Americas Inc given. The stock rating was upgraded by SunTrust to “Buy” on Wednesday, February 14. The company rating was maintained by RBC Capital Markets on Tuesday, February 13. On Tuesday, February 13 the rating was maintained by Robert W. Baird with “Buy”. Listed here are Charles River Laboratories International, Inc. (NYSE:CRL) PTs and latest ratings.

24/04/2018 Broker: Jefferies Rating: Buy New Target: $129.0000 Maintain
20/04/2018 Broker: MUFG Securities Americas Inc Rating: Hold New Target: $115.0000 Initiate
20/04/2018 Broker: Mitsubishi UFJ Rating: Neutral New Target: $115 Initiates Coverage On
14/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $94 New Target: $102 Maintain
13/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $116.0 Maintain
13/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $123.0 Maintain
14/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $110 New Target: $120 Maintain
14/02/2018 Broker: SunTrust Old Rating: Hold New Rating: Buy Upgrade
22/01/2018 Broker: SunTrust Rating: Hold Downgrade
19/01/2018 Broker: Evercore Rating: In-Line New Target: $117 Initiates Coverage On

Ticker’s shares touched $103.65 during the last trading session after 0.49% change.Currently Charles River Laboratories International, Inc. is uptrending after 21.28% change in last May 16, 2017. CRL has also 283,740 shares volume. The stock outperformed the S&P500 by 9.73%.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The firm is worth $4.97 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).40.86 is the P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

More recent Charles River Laboratories International, Inc. (NYSE:CRL) news were brought out by Benzinga.com, Businesswire.com and Globenewswire.com. The first one has “Earnings Scheduled For May 10, 2018” as a title and was brought out on May 10, 2018. The next is “Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations” on May 10, 2018. And last was brought out on April 20, 2018, called “New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River …”.

Charles River Laboratories International, Inc. (NYSE:CRL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: